[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rutgers, The State University of New Jersey\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":643},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,116,0,25,[9,47,68,94,121,144,169,200,226,258,280,302,329,355,373,413,435,458,482,509,530,553,576,600,620],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100652410","the-impact-of-cigar-pack-marketing-with-natural-themes-on-young-adults-100652410",false,"NCT07773415","The Impact of Cigar Pack Marketing With \"Natural\" Themes on Young Adults","Impact of Cigar Marketing With \"Natural\" Themes","Inclusion Criteria:\n\n* English survey takers in the US\n* Age: Young adults ages 18-34\n* Cigar Experience: Study aims to include a mix of young adults who have:\n* ever used any type of cigar or cigarillo (including for blunt use)\n* used any type of cigar or cigarillo in the past 12 months (including for blunt use)\n* never used, but are susceptible to using any type of cigar or cigarillo in the future. Susceptible is defined as people who respond \"definitely yes\", probably yes\" or \"probably not\" (vs. \"definitely not\" responses) to any of four questions asking prospective participants if they have 1) ever been curious about cigar\u002Fcigarillos, 2) if they think they will try a cigar\u002Fcigarillo soon 3) if they think they will use a cigar\u002Fcigarillo in the next year and 4) if they would use a cigar\u002Fcigarillo if they were offered one by a best friend.\n\nExclusion Criteria:\n\n* Research panel participants who do not meet the criteria outlined above will be excluded.",true,"ALL","18 Years","34 Years",{"count":22,"type":23},3500,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this online survey experiment is to examine the effect of \"natural\" descriptors and images on cigar packs among young adults (ages 18-34) who have either used cigars in the past year or are non-users who are susceptible to use. The study will compare effects of cigar pack images with or without \"natural\" descriptors (that explicitly say \"natural\" vs. imply naturalness with the word \"leaf\"), with or without \"natural\" images (such as leaves), and with or without images of cigar sticks (that are rough-cut (e.g., darker wrapper color with more visible leaf lines) vs. smooth) on product perceptions, intentions to use cigars, and recall.\n\nParticipants will be randomized to one of 18 conditions and will be shown four cigar pack images from various brands within their condition. After seeing the images, they will complete survey questions assessing product perceptions, intentions, and recall, and will complete other embedded tasks in the survey, before being debriefed about the harms of cigars.",[29],"Tobacco Product Beliefs and Use",[31,32,33,34],"cigars","cigarillos","tobacco marketing","natural claims","NOT_YET_RECRUITING","2026-08-14",{"date":38,"type":39},"2026-08-19","ACTUAL",{"date":41,"type":23},"2026-08",{"date":43,"type":23},"2026-11",{"name":45,"class":46},"Rutgers, The State University of New Jersey","OTHER",{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100638261","hola-intervention-pilot-100638261","NCT07576530","HOLA Intervention Pilot","Heightening Oncologist-Latino\u002Fa Cancer Patient Alliances (HOLA) Intervention Pilot Study","Inclusion Criteria:\n\n1. identifying as ethnically Latino;\n2. locally advanced or metastatic cancer (pancreaticobiliary, esophagogastric, hepatocellular carcinoma, lung, or gynecological cancer) AND have experienced disease progression on at least first-line chemotherapy\n3. ability to provide informed consent.\n\nExclusion Criteria:\n\n1. not fluent in English or Spanish;\n2. severely cognitively impaired (as measured by Short Portable Mental Status Questionnaire scores of \\\u003C 6 during screening);\n3. too ill or weak to complete the interviews (as judged by interviewer);\n4. children and young adults under age 21\n5. patients deemed inappropriate for the study by their treating oncologist.","89 Years",{"count":56,"type":23},32,[26],"The patient-clinician relationship is fundamental to providing high-quality patient-centered medical care. A therapeutic alliance (TA) is a patient clinician relationship that is characterized by mutual caring, trust, understanding, and respect. A strong TA between oncologists and patients with advanced cancer is associated with several positive health outcomes for patients and caregivers. However, previous work showed a stark disparity in the TA for Latino\u002Fa patients with advanced cancer vs. non-Latino\u002Fa white patients. The overall objective of this study is to pilot the Heightening Oncologist-Latino\u002Fa cancer patient Alliances (HOLA) intervention to assess its feasibility, acceptability, and appropriateness, and the preliminary efficacy of the intervention's impact on the TA between oncologists and their Latino\u002Fa patients with advanced cancer. The HOLA intervention will teach oncologists specific evidence based skills and behaviors for promoting a TA with Latino\u002Fa advanced cancer patients through the integration of patient-centered communication techniques that are aligned with Latino\u002Fa cultural values via commonly encountered clinical scenarios. The investigators will pilot test the HOLA intervention with eight oncologists and 32 of their patients, half (n=16 patients) who are under the care of an oncologist who will be randomized to receive the TA intervention (n=4 oncologists), and half (n=16 patients) who are under the care of an oncologist (n=4 oncologists) who was randomized to usual care. The feasibility, acceptability, and appropriateness of the intervention will be assessed using standard measures. Preliminary efficacy will be determined by comparing the mean TA scores for the oncologists who were randomized to receive the intervention to the mean TA scores for the oncologists who were randomized to usual care.",[60],"Therapeutic Alliances","2026-08-12",{"date":36,"type":39},{"date":64,"type":23},"2026-09",{"date":66,"type":23},"2026-10",{"name":45,"class":46},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":17,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":24,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100641565","developing-and-implementing-hpv-screened-100641565","NCT07657104","Developing and Implementing HPV SCREENED","Developing and Implementing HPV SCREENED (Self-Collection REach and ENgagement in Emergency Departments) to Improve Cancer Equity","Inclusion Criteria:\n\n* biological women,\n* no prior hysterectomy or cervical cancer,\n* not pregnant,\n* last Pap \\>3 years, last co-test \\>5 years, or last HPV alone test \\>5 years,\n* speak English or Spanish,\n* has a working cellphone,\n* NJ residency\n* ED patient\n\nExclusion Criteria:\n\n* currently pregnant (as diagnostic procedures for cervical cancer are often deferred during pregnancy);\n* previous hysterectomy;\n* previous diagnosis of cervical cancer;\n* current menses","FEMALE","30 Years","65 Years",{"count":79,"type":23},100,[26],"This study will assess the feasibility of implementing HPV self-sampling as a primary cervical cancer screening strategy for under-screened women in the emergency department (ED). Eligible participants will receive education and an HPV self-sampling kit to complete in the ED. Individuals with HPV-positive results will be guided to follow-up care at a local clinic.",[83,84],"Cervical Cancer Screening","Human Papilloma Virus","2026-08-10",{"date":87,"type":39},"2026-08-11",{"date":89,"type":23},"2026-08-20",{"date":91,"type":23},"2027-09-30",{"name":45,"class":46},2,{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":17,"sex":18,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":24,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":93},"100500008","motivational-refinements-for-facilitating-reinforcement-schedule-thinning-100500008","NCT05790668","Motivational Refinements for Facilitating Reinforcement Schedule Thinning","Inclusion Criteria:\n\n* boys and girls from ages 3 to 17\n* destructive behavior that occurs at least 10 times a day, despite previous treatment\n* destructive behavior reinforced by social consequences\n* stable protective supports for self-injurious behavior (e.g., helmet) with no anticipated changes during enrollment\n* on a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free\n* stable educational plan and placement with no anticipated changes during the child's treatment\n\nExclusion Criteria:\n\n* patients who do not meet the inclusion criteria\n* patients currently receiving 15 or more hours per week of treatment for their destructive behavior\n* Diagnostic and Statistical Manual-5 diagnosis of Rett syndrome or other degenerative conditions (e.g., inborn error of metabolism)\n* a comorbid health condition or major mental disorder that would interfere with study participation\n* occurrence of self-injury during study assessments that presents a risk of serious or permanent harm (e.g., detached retinas) based on routine clinical-risk assessment\n* patients requiring changes to protective supports for self-injury or drug treatment, but investigators will invite these patients to participate when protective supports and drug regimen are stable","3 Years","17 Years",{"count":103,"type":23},30,[26],"Destructive behavior represents a comorbid condition of developmental disability for which risk increases with intellectual disability severity, communication deficits, and co-occurring autism spectrum disorder. Destructive behavior, such as self-injurious behavior and aggression, causes harm to the child and others and increases the risk for institutionalization, social isolation, physical restraint, medication overuse, and abuse. Clinicians have used functional analyses to identify the variables that reinforce destructive behavior and to develop effective, function-based treatments. Functional communication training (FCT) is an empirically supported, function-based treatment that decreases destructive behavior. Using FCT, the clinician teaches the child to use a functional communication response (FCR) to request the reinforcer maintaining destructive behavior, while placing destructive behavior on extinction. For example, if functional analysis results showed that attention reinforced destructive behavior, the clinician would provide attention when the child used the FCR (\"Play with me, please\") and would not provide attention for destructive behavior. Two limitations of FCT are that (a) schedules of reinforcement maintaining the FCR must often be thinned gradually to levels that are practical for caregivers to implement consistently in the home and in the community, and (b) this necessary process of reinforcement schedule thinning regularly causes destructive behavior to increase following initially effective treatment, a form of treatment relapse called resurgence. The current project aims to improve these limitations of FCT by (a) hastening the process of reinforcement schedule thinning by removing unnecessary schedule-thinning steps using the results of a progressive interval assessment and (b) mitigating the resurgence of destructive behavior by providing stimuli that highly compete with the reinforcer maintaining destructive behavior. The investigators will conduct a randomized clinical trial to evaluate the extent to which these two promising refinements to FCT improve the process of reinforcement schedule thinning, and an exploratory experiment will examine the interactive effects of these two approaches. This novel project has the potential to substantially improve standards of care guiding the treatment of severe destructive behavior and to improve the long-term outcomes for children and families afflicted by these debilitating behavior disorders.",[107,108],"Decreasing Destructive Behavior","Increasing Functional Communicative Behavior",[110,111,112,113],"functional communication training","reinforcement schedule thinning","resurgence","treatment relapse","RECRUITING",{"date":61,"type":39},{"date":117,"type":39},"2023-10-24",{"date":119,"type":23},"2028-08-31",{"name":45,"class":46},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":24,"phases":130,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100651591","phase-2-luminal-bladder-cancer-effective-response-to-neoadjuvant-chemotherapy-lumber-nac-100651591","NCT07762586","Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)","Inclusion Criteria:\n\n* ▪ Inclusion Criteria\n\n  * Willing and able to provide informed consent\n  * Age ≥18 years old\n  * Eligible to receive standard of care systemic neoadjuvant therapy\n  * Eastern Cooperative Group (ECOG) performance status of 0-1\n  * Documented histologically confirmed urothelial muscle-invasive bladder cancer\n  * cT2N0M0 bladder cancer based on pre-TURBT bimanual exam and cross-sectional imaging performed within 8 weeks of surgery or initiation of NAT.\n  * Willing to undergo RC with urinary diversion\n  * No signs of extravesical disease on pre-TURBT conventional imaging\n  * Variant histology is allowed so long as the tumor is predominantly urothelial carcinoma.\n  * No presence of LVI on TURBT\n  * Decipher Bladder GSC test result\n  * Ineligible for or refusing TMT\n  * No cN+\n  * The population is adult men or women of any ethnicity diagnosed with muscle-invasive bladder cancer.\n\nExclusion Criteria:\n\n* Patients under 18 years old. Considering the minimal incidence of bladder cancer among the pediatric population, children are not eligible for this study.\n* Not willing or unable to give informed consent.\n* Clinical or pathological evidence of metastatic disease, including, non-regional lymph nodes, visceral lesions, and bone lesions.\n* Significant hepatic impairment (Serum bilirubin \\> 1.5x upper limit of normal).\n* Significant renal impairment (creatinine clearance \\\u003C30 ml\u002Fmin).\n* Predominant variant histology (i.e. nested, micropapillary, sarcomatoid, plasmacytoid, small cell)6\n* cT3 bladder cancer on pre-TURBT bimanual exam or with hydronephrosis on cross-sectional imaging performed within 8 weeks of surgery or initiation of NAT\n* TURBT specimen with lymphovascular invasion (LVI) cT4 or unresectable bladder cancer\n* Concurrent diagnoses of other, non-urothelial, malignancies or prior malignancy diagnoses within the past three years. Exceptions, determined at the discretion of the principal investigator, include squamous cell carcinoma, basal cell carcinoma, or other low-grade cancer not expected to progress or require surgical\u002Fsystemic therapy.\n* Prior history of systemic treatment for non-urothelial malignancies in the past three years, including chemotherapy and immunotherapy.\n* Prior diagnosis or evidence of psychiatric or medical conditions that may prevent patients from giving full and properly informed consent.\n* Any medical, familial, psychiatric, or geographic considerations that may prevent patients from study participation or follow-up required by the study protocol\n* Patients (cN+) are excluded from participation and are not eligible for enrollment.\n* Prisoners, Individuals without Decisional Capacity, and Pregnant Women will be excluded.","90 Years",{"count":129,"type":23},60,[131],"PHASE2","This study is a two-arm phase II randomized trial investigating patients with luminal subtype muscle-invasive bladder cancer (MIBC) receiving neoadjuvant therapy (NAT) followed by cystectomy compared to those receiving upfront cystectomy.",[134],"Bladder Cancer","2026-08-07",{"date":137,"type":39},"2026-08-13",{"date":139,"type":39},"2026-07-10",{"date":141,"type":23},"2029-07",{"name":45,"class":46},1,{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":24,"phases":153,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":143},"100581028","effects-of-latin-dancing-on-sleep-quality-in-hispanic-cancer-survivors-100581028","NCT06844981","Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors","Moviendo Las Caderas: Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors","Inclusion Criteria:\n\n* Be 18 years of age or older\n* Self-identify as Hispanic and\u002For Latino(a)\n* Have a confirmed diagnosis of a solid tumor or hematologic malignancy\n* Must have completed primary cancer treatment 3+ months prior to enrollment (e.g., chemotherapy, surgery, and\u002For radiation therapy but may be on hormonal therapy and\u002For immunotherapy or other long-term therapies)\n* Have sleep disturbance (indicated by a response of 3 or more on the MD Anderson Symptom Inventory sleep question by using an 11-point scale anchored by 0 \\[no sleep disturbance\\] and 10 \\[worst possible sleep disturbance\\]\n* Be able to read and understand English and\u002For Spanish\n* Physically Inactive (\\\u003C150 minutes of vigorous exercise\u002Fweek within the past 3 months)\n\nExclusion Criteria:\n\n* Current regular Latin dancing practice within the past year (2-3 times a week over a period of two months that is not interrupted).\n* Inability to speak and read English or Spanish proficiently\n* Inability to understand informed consent\n* Medical conditions that can cause sleep impairment: sleep apnea, restless leg syndrome, shift work\n* Regular use of a walker or wheelchair\n* Healing or unhealed fractures\n* Heart failure\n* Life expectancy \\\u003C12 months\n* Unwilling to be randomized to study arms and\u002For commit to 8 weeks of classes and a follow-up assessment",{"count":152,"type":23},50,[26],"The primary objective is to assess the feasibility, acceptability and explore the impact of a culturally appropriate Latin Dance intervention vs. Usual Care on sleep quality for Hispanic cancer survivors.\n\nSecondary objectives are to examine the preliminary efficacy of a culturally appropriate Latin Dance intervention on secondary cancer- and treatment-related side effects (e.g., Quality of Life, distress, insomnia, fatigue).",[156,157],"Cancer Survivorship","Sleep Disturbances",[159,156,157,160,161],"Cancer","Hispanic Cancer Survivors","Latin Dancing","2026-08-06",{"date":135,"type":39},{"date":165,"type":39},"2026-04-01",{"date":167,"type":23},"2027-03",{"name":45,"class":46},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":176,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":24,"phases":179,"briefSummary":181,"conditions":182,"keywords":186,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":4},"100650418","phase-1-ai-dbt-for-serious-illness-100650418","NCT07748312","AI-DBT For Serious Illness","Pilot Testing AI-Delivered Dialectical Behavioral Therapy Skills and Coaching in Older Patients With Serious Illness","Inclusion Criteria:1) Aged 60+, 2) diagnosis of serious, life limiting illness including stage 4 breast, prostate, or colon cancer; stage 3b or 4 lung or blood cancer, New York Heart Association Stage 3 or 4 CHF, or COPD with hypercapnia74 or CKD stage 4 or ESRD; 3) psychological distress rated 4 or higher on the distress thermometer;75-77 4.) has access to a mobile phone and 5.) speaks English or Spanish fluently.\n\n\\-\n\nExclusion Criteria:\n\n\\-","60 Years",{"count":178,"type":23},80,[180],"PHASE1","Lay \u002F General Audience Summary Many older adults living with serious illnesses experience high levels of emotional distress, including anxiety, sadness, fear, and feeling overwhelmed. These feelings often worsen as illness progresses and can make physical symptoms harder to manage, reduce quality of life, and increase the use of medications. Unfortunately, many people with serious illness cannot access mental health care because there are not enough providers, services are hard to reach, appointments are physically exhausting, or care is not available in their language.\n\nThis study will test a new way of delivering emotional support that does not require in-person therapy. The program teaches practical coping skills that help people manage strong emotions and stress. These skills are delivered through short videos and daily supportive check-ins using an automated phone or text system that people can use from home. The system is available in many languages and can be used on basic mobile phones, making it accessible to a wide range of patients.\n\nWe will enroll older adults with serious illnesses such as cancer, heart disease, lung disease, or kidney disease who are experiencing emotional distress. Participants will be randomly assigned to receive either their usual medical care alone or usual care plus the new skills program. We will examine whether people find the program easy to use, helpful, and acceptable, and whether it improves their confidence in managing difficult emotions and reduces distress.\n\nThe goal of this project is to develop a low-burden, widely accessible way to support emotional well-being for people living with serious illness. If successful, this approach could expand access to mental health support for patients who currently have few options.",[183,184,185],"Serious Illness","Distress, Emotional","Distress",[187,188,189,190,191],"serious illness","mental health","AI","DBT","distress","2026-08-03",{"date":194,"type":39},"2026-08-05",{"date":196,"type":23},"2026-10-01",{"date":198,"type":23},"2028-05-15",{"name":45,"class":46},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":17,"sex":18,"minAge":207,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":24,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":225,"locationsCount":143},"100645399","sun-safe-together-a-digital-skin-cancer-prevention-intervention-for-adolescents-and-their-parents-100645399","NCT07681791","Sun Safe Together: A Digital Skin Cancer Prevention Intervention for Adolescents and Their Parents","A Digital Skin Cancer Prevention Intervention for Adolescents and Their Parents","Inclusion Criteria:\n\nParents and teens are participating as dyads, meaning both the parent and the teen need to be deemed eligible based on the criteria below to be able to participate.\n\nTeens\n\n* Must be ages 13-17 years\n* Live with study parent equal to or greater than half time in US\n* Have experienced sunburn or indoor tanned in the last year or have a suboptimal sun protection score\n* Have no personal history of melanoma or severe medical condition that prevents participation\n* Have access to smartphone\n* Speak and read English\n\nParents\u002FGuardians\n\n* Must be age 18 or older\n* Live with a teen equal to or greater than half time in US\n* Have a teen who had experienced sunburn or indoor tanned in the last year or have a suboptimal sun protection score\n* Have no personal history of melanoma or severe medical condition that prevents participation\n* Have internet at home, a Facebook account, and be willing to use Facebook daily\n* Have access to smartphone\n* Speak and read English","13 Years",{"count":209,"type":23},104,[26],"The goal of this pilot clinical trial is to learn if a digital intervention to improve sun safety, Sun Safe Together (SST), is feasible and acceptable to teenagers and their parents.",[213],"Skin Cancer Prevention",[215,216,217,218,219,220],"Sun Safety","Teens","Messages","Teen health","Parents","Education",{"date":194,"type":39},{"date":41,"type":23},{"date":224,"type":23},"2027-12",{"name":45,"class":46},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":75,"minAge":19,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":24,"phases":236,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":257},"100611692","mobile-based-obstetric-monitoring-for-pregnancies-complicated-by-hypertension-andor-diabetes-mom-hd-100611692","NCT07243886","Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and\u002For Diabetes (MOM-HD)","Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and\u002For Diabetes (MOM-HD): a Type II Hybrid Implementation-Effectiveness Trial","MOM-HD","Inclusion Criteria:\n\n* Pregnant women receiving antenatal care at RCT site\n* Diagnosed with one of the following:\n\n  * Chronic hypertension (sustained systolic BP ≥140 mm Hg and\u002For diastolic BP ≥90 mm Hg, or on antihypertensive treatment before 20 weeks of gestation)\n  * Gestational hypertension or preeclampsia without severe features (sustained systolic BP ≥140 mm Hg and\u002For diastolic BP ≥90 mm Hg after 20 weeks of gestation)\n  * Gestational diabetes\n* Age 18 years or older\n* Access to a smartphone\n* Gestational age ≤ 34 weeks at enrollment\n* Able to read and write\n\nExclusion Criteria:\n\n* Multifetal pregnancies\n* Apparent communication difficulties (e.g., hearing, speech, or cognitive impairments), as judged by research assistants\n* Unable to understand the Nepali language\n* Severe maternal illness or any condition that precludes active study participation (e.g., preeclampsia with severe features, eclampsia, HELLP syndrome, or other conditions requiring inpatient management)\n* Declines to provide informed consent",{"count":235,"type":23},864,[26],"Hypertensive disorders during pregnancy (HDP) and gestational diabetes (GDM) are among the leading complications in pregnancy, significantly contributing to global maternal and fetal morbidity and mortality. (1,2,3) Effective management of HDP and GDM hinges on regular monitoring of blood pressure (BP) and blood glucose (BG) to ensure adequate control and timely interventions for maternal and fetal well-being. Telemonitoring offers a promising and cost-effective alternative by enabling pregnant individuals to monitor BP and BG at home and share real-time results with healthcare providers, facilitating informed clinical decision-making and timely interventions.\n\nHere the investigators propose to conduct a Hybrid Type II Effectiveness-Implementation Randomized Controlled Trial (RCT) to assess the effectiveness and evaluate the implementation of the MOM-HD (Mobile-based Obstetric Monitoring for Hypertension and\u002For Diabetes) program, a mobile app-based perinatal telemonitoring program, in real-world clinical settings in Nepal. To address the study aims, the investigators will recruit 864 women who are newly diagnosed with HDP and GDM from three metropolitan hospitals and randomly assign them to either (i) MOM-HD + standard care or (ii) standard care alone, from enrolment in pregnancy to 6 weeks postpartum. Primary and secondary clinical outcomes will be assessed at delivery, and at 6 weeks postpartum. The investigators hypothesize that compared to standard care, the use of MOM-HD in addition to standard care will result in lower systolic BP levels, lower incidence rate for the composite adverse perinatal outcome of either perinatal loss, neonatal intensive care unit admission, primary cesarean delivery or labor induction, and lower proportion of days with elevated systolic BP or BG readings between recruitment and 6 weeks postpartum. A convergent mixed-methods approach will be used to assess implementation and maintenance outcomes using the RE-AIM framework (4), and economic sustainability will be assessed by collecting primary cost data.",[239,240],"Gestational Diabetes","Hypertensive Disorder of Pregnancy",[242,243,244,245,246,247,248],"pregnancy","telemonitoring","mHealth","GDM","HDP","Nepal","implementation","2026-07-29",{"date":251,"type":39},"2026-07-31",{"date":253,"type":39},"2026-06-30",{"date":255,"type":23},"2030-12-31",{"name":45,"class":46},3,{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":24,"phases":267,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":143},"100484525","phase-3-high-dose-buprenorphine-bup-induction-in-the-emergency-department-ed-100484525","NCT05589181","High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)","Safety and Efficacy of High Dose Buprenorphine Induction in Fentanyl Positive Emergency Department Patients","Inclusion Criteria:\n\n* Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study\n* Treated in the ED during screening hours\n* Meet DSM-5 diagnostic criteria for moderate to severe OUD\n* Clinical Opioid Withdrawal Score (COWS) score ≥ 8\n* Urine toxicology positive for fentanyl\n* Able to speak English or Spanish sufficiently to understand study procedures\n\nExclusion Criteria:\n\n* UDS positive for methadone.\n* Be pregnant determined by urine human chorionic gonadotropin (uHCG) testing\n* Have an unstable medical or psychiatric condition including suicidality requiring hospitalization\n* Require ongoing opioids for pain management\n* Be enrolled in formal addition treatment including by court order anytime within the last 30 days. Patients enrolled in formal addiction treatment not receiving Medications for Opioid Use Disorder (MOUD) are eligible\n* Be a prisoner or in custody at the time of the index visit\n* Have any pending legal status or pending legal action that could prohibit full participation in or compliance with study procedures.\n* Unable to provide one additional point of contact other than themselves\n* Unwilling to follow study procedures\n* Have prior enrollment in the current study\n* Have a known allergy or hypersensitivity to BUP\n* Have been engaged in formal addiction treatment in the 30-days prior to the ED visit (this does not include addiction treatment or residential programs where MOUD is not given (e.g. behavioral counseling, abstinence programs, NA)\n* Have received naloxone in the 60-minutes prior to the anticipated first transmucosal (TM) BUP administration\n* Is undergoing concurrent treatment with another investigational agent or enrolment in another clinical study",{"count":266,"type":23},140,[268],"PHASE3","This project, involving two distinct clinical trials, tests whether induction to a higher than currently recommended buprenorphine (BUP) induction dose is safe and can improve the proportion of patients who engage in comprehensive addiction services within 7-day of induction.\n\nTrial 1 is a head-to-head comparison of the safety, tolerability and feasibility of high dose BUP induction (32 mg). The study involves two cohorts, (1) a 12mg cohort (standard) to determine baseline data and (2) a 32 mg (high dose) cohort. If the 32mg is intolerable, a 24 mg dose may be evaluated. Trial 2 is a small pilot multicenter randomized, double blinded, clinical trial in 80 participants (randomized 1:1) that will provide preliminary information on efficacy with the primary outcome being engagement in comprehensive addiction treatment 7-days post BUP induction. In collaboration with National Institute on Drug Abuse (NIDA), the research team have determined that there must be a minimum increase in engagement in comprehensive addiction treatment of 15% at 7-days in the high dose induction group to justify a larger future clinical trial.",[271],"Opioid Use Disorder","2026-07-28",{"date":274,"type":39},"2026-07-30",{"date":276,"type":39},"2023-04-06",{"date":278,"type":23},"2026-12-31",{"name":45,"class":46},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":24,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":143},"100467980","mysmartskin-online-skin-self-exam-intervention-for-melanoma-survivors-100467980","NCT05373823","MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors","A Digital Intervention to Improve Skin Self-examination Among Melanoma Survivors","Inclusion Criteria:\n\n* Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma\n* Three months to five years post-surgery\n* No current evidence of cancer\n* Not adherent to thorough SSE (i.e., did not check entire body at least once during the past three months)\n* ≥ 18 years old\n* Internet access\n* Able to speak\u002Fread English\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Children",{"count":288,"type":23},385,[26],"This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key implementation outcomes (e.g., cost, adoption) as well as contextual factors important for scale-up in community and health care settings where melanoma survivors receive follow-up care. A type 1 hybrid effectiveness-implementation design allows us to engage multilevel stakeholders throughout this process, evaluate the effectiveness of the enhanced MSS, and identify critical factors for wide-scale implementation. Aim 1 will focus on enhancing the previous version of MSS by collaborating with multi-level stakeholders in qualitative interviews and usability testing. Aim 2 will evaluate the effects of enhanced MSS on thorough skin-self examinations (SSE) in a randomized-control trial (RCT) and examine its impact on the diagnosis of new\u002Frecurrent melanomas. Aim 3 will focus on assessing selected implementation outcomes and identify factors relevant to future scale-up for widespread dissemination and implementation.",[292],"Melanoma",[294],"Self-Examination","2026-07-27",{"date":272,"type":39},{"date":298,"type":39},"2023-03-06",{"date":300,"type":23},"2027-03-31",{"name":45,"class":46},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":176,"maxAge":127,"enrollmentInfo":309,"targetDuration":4,"studyType":24,"phases":310,"briefSummary":311,"conditions":312,"keywords":316,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":143},"100521697","phase-2-commets--combination-mci-metabolic-syndrome-100521697","NCT06072963","COMMETS- Combination MCI Metabolic Syndrome","Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study","Inclusion Criteria:\n\n* Diagnosis of MCI (based on a MOCA \\\u003C27 and a clinical dementia rating scale \\[CDR\\] score of 0.5 representing questionable dementia).\n* Diagnosis of MetS -requiring a) abdominal obesity (waist circumference \\>102cm for men and \\>88cm for women), and b) glucose intolerance (fasting glucose\\>110 mg\u002FdL) and at least one of the following-c) dyslipidemia (high triglycerides \\[\\>150 mg\u002FdL\\] and low HDL \\[\\\u003C40mg\u002FdL for men and \\\u003C50 mg\u002FdL for women\\]), or d) elevated blood pressure (\\>130\u002F\\>85 mmHg).\n* Fluent in Hebrew\n* The study requires an active study partner\n\nExclusion Criteria:\n\n* Diabetes (of any type)\n* Taking medications that may affect glucose metabolism (including a GLP-1RA).\n* Diagnosis of dementia and its subtypes, conditions that may directly affect cognition,\n* short life expectancy or a medical condition that precludes consistent participation in the study,\n* contraindications to either insulin or Semaglutide.\n* Medications that may affect glucose metabolism such as corticosteroids.",{"count":178,"type":23},[131],"The investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired cognition through vascular mechanisms, in older adults with MetS (metabolic syndrome) and MCI (Mild Cognitive Impairment), who are enriched for cerebrovascular disease and at high dementia risk. The study will focus on cognitive and biological outcomes, allowing identification of relevant mechanisms.",[313,314,315],"Alzheimer Disease","Mild Cognitive Impairment","Metabolic Syndrome",[317,314,318,319,320,321],"Alzheimer disease","Metabolic syndrome","Dementia","Semaglutide","Intranasal insulin","2026-07-23",{"date":295,"type":39},{"date":325,"type":39},"2024-01-30",{"date":327,"type":23},"2028-12-01",{"name":45,"class":46},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":100,"maxAge":101,"enrollmentInfo":336,"targetDuration":4,"studyType":24,"phases":338,"briefSummary":339,"conditions":340,"keywords":342,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":93},"100607455","phase-2-impact-of-rada16-use-on-outcomes-following-tonsillectomy-in-children-100607455","NCT07188779","Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children","RADA16 for Ped","Inclusion Criteria:\n\nChildren aged 3-17 years undergoing tonsillectomy +\u002F- adenoidectomy CPT codes\n\n* 42820 (Tonsillectomy and adenoidectomy; younger than age 12)\n* 42821 (… age 12 or over)\n* 42825 (Tonsillectomy; primary or secondary; younger than age 12)\n* 42826 (… age 12 or over)\n* 42830 (Adenoidectomy, primary; younger than age 12)\n* 42831 (… age 12 or over)\n* 42835 (Adenoidectomy; secondary; younger than age 12)\n* 42836 (… age 12 or over)\n\nExclusion Criteria:\n\n* Children with bleeding disorders or other hematologic malignancy or taking anticoagulant medications Developmental delay affecting pain reporting Children with known allergies to RADA16 components Children with prior tonsillectomy or tonsillotomy Children undergoing tonsillectomy with concern for cancer, Children taking opioids chronically prior to surgery, Anyone pregnant women, incarcerated individuals, children unable to speak English or Spanish",{"count":337,"type":23},134,[131],"The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.Participants will:\n\nUndergo tonsillectomy procedure. Receive and fill out a survey sent via email every 2 days following their procedure for 15 days, plus an additional survey on day 30, and track their symptoms.",[341],"Postoperative Pain",[343,344,345,346],"tonsillectomy","adenoidectomy","hemostasis","postop complications","2026-07-21",{"date":349,"type":39},"2026-07-22",{"date":351,"type":39},"2026-07-09",{"date":353,"type":23},"2027-12-01",{"name":45,"class":46},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":24,"phases":363,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":93},"100597592","phase-3-rada16-for-adult-tonsillectomy-100597592","NCT07060495","RADA16 for Adult Tonsillectomy","Use of Novel Self-assembling RADA-16 Peptide Matrix to Decrease Postoperative Epistaxis for Tonsillectomy Surgeries","Inclusion criteria:\n\nAdults undergoing tonsillectomy (CPT codes)\n\nExclusion criteria:\n\nPatients undergoing adenoidectomy or uvulopalatopharyngoplasty in addition to tonsillectomy\n\nPatients who have had prior tonsillectomy or tonsillotomy\n\nPatient undergoing tonsillectomy with concern for malignancy\n\nPatients who are on opioids chronically prior to surgery\n\nPatients with an additional indication for pain management (i.e. unrelated to tonsillectomy)\n\nPatients who have been diagnosed with a bleeding disorder or hematologic malignancy\n\nPatients who are on anticoagulants\n\nThe following at-risk populations:\n\nAnyone under age 18\n\nPregnant women\n\nPrisoners\n\nAdults unable to consent (anyone lacking capacity)",{"count":337,"type":23},[268],"The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following tonsillectomy procedures.\n\nResearchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.\n\nParticipants will:\n\n* Undergo tonsillectomy procedure.\n* Receive and fill out a survey sent via email every 2 days following their procedure for 15 days and track their symptoms.",[341],[343,345,346],{"date":322,"type":39},{"date":369,"type":39},"2025-09-12",{"date":371,"type":23},"2026-12-01",{"name":45,"class":46},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":383,"phases":4,"briefSummary":384,"conditions":385,"keywords":395,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":410,"leadSponsor":412,"locationsCount":143},"100647771","rutgers-university-study-of-the-genetics-of-blood-cancers-100647771","NCT07714044","Rutgers University Study of the Genetics of Blood Cancers","The Rutgers University Study of the Genetics of Blood Cancers","Inclusion Criteria:\n\n* age 18 years or older\n* currently living in the United States\n* have access to the internet and a computer, laptop, tablet or smartphone\n* willing to provide written informed consent for participation\n* willing to provide DNA via a saliva sample using a collection kit mailed to your home\n* willing to complete a survey with questions about health related to the study of blood cancer.\n\nExclusion Criteria:\n\n* Not able to meet or fulfill any of the inclusion criteria","110 Years",{"count":382,"type":23},10000,"OBSERVATIONAL","The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.",[386,387,388,389,390,391,392,393,394],"Blood Cancers","Blood Cancer","Leukemia","Lymphoma","Myeloma","Hematologic Cancer","Hematologic Malignancies","Hematologic Neoplasm","Hematologic Tumors",[396,397,398,399,400,401,402,403,404,405],"genetics","blood cancer","blood cancers","leukemia","lymphoma","myeloma","hematologic cancer","hematologic malignancy","hematologic tumor","hematologic neoplasm","2026-07-15",{"date":408,"type":39},"2026-07-20",{"date":41,"type":23},{"date":411,"type":23},"2029-08",{"name":45,"class":46},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":24,"phases":422,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":93},"100518673","phase-3-motivational-interviewing-and-mindfulness-oriented-recovery-enhancement-100518673","NCT06033599","Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement","Motivational Interviewing (MI) and Mindfulness-Oriented Recovery Enhancement (MORE) for Tobacco Dependence and Other Drug Use in Methadone Treatment","Inclusion Criteria:\n\n* English-speaking\n* Age ≥18\n* Currently on methadone; and 4) currently smoke cigarettes.\n\nExclusion Criteria:\n\n* Severe cognitive impairment (score \\>23 on Mini Mental Status Exam) or psychosis (positive SCID Psychotic Screen)\n* Suicidal risk (score ≥7 on Suicidal Behaviors Questionnaire)\n* Inability to attend or fully participate in intervention sessions or assessments\n* Previous formal mindfulness training (e.g., MBSR, MBRP) or MORE (from the R21 or R33\n* Currently taking smoking cessation pharmacotherapy or participating in smoking cessation counseling\n* Any contraindications for NRT\n* Currently or soon planning to be pregnant or breastfeeding.",{"count":421,"type":23},420,[268],"The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, and other drug use.",[425,426,427],"Polysubstance Abuse","Opioid Use","Tobacco Use",{"date":429,"type":39},"2026-07-17",{"date":431,"type":39},"2023-09-05",{"date":433,"type":23},"2028-08",{"name":45,"class":46},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":24,"phases":442,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":4},"100645848","phase-4-effects-of-melatonin-on-sleep-architecture-of-critically-ill-patients-in-the-icu-100645848","NCT07691996","Effects of Melatonin on Sleep Architecture of Critically Ill Patients in the ICU","Inclusion Criteria:\n\n* 18 years or older, admitted to the ICU\n* Expected length of stay of at least 48 hours\n* Not mechanically ventilated\n* Able to take oral medications.\n* Hemodynamically stable as determined by the treating ICU physician\n* Able to provide informed consent or have consent provided by a legally -authorized representative.\n\nExclusion Criteria:\n\n* Mechanically ventilated\n* Currently using melatonin prior to ICU admission,\n* Have neurological conditions that may significantly alter sleep architecture, such as traumatic brain injury, stroke, or severe dementia.\n* Pregnant or lactating individuals\n* Those individuals with a comfort measures-only status",{"count":103,"type":23},[443],"PHASE4","This is a pilot study to examine the effects of melatonin on the sleep patterns of critically ill patients. Patients will have their sleep patterns measured with a device attached to their head with a headband then be given a dose of melatonin. Their participation in the study will last two days.",[446,447,448,449,450],"Critical Illness","ICU","ICU Hospitalization","Melatonin","Sleep",{"date":452,"type":39},"2026-07-13",{"date":454,"type":23},"2026-09-01",{"date":456,"type":23},"2028-01",{"name":45,"class":46},{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":24,"phases":466,"briefSummary":467,"conditions":468,"keywords":471,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":479,"leadSponsor":481,"locationsCount":93},"100635180","evaluating-the-use-of-prehospital-lung-ultrasound-in-ems-a-multicenter-pilot-study-100635180","NCT07549334","Evaluating the Use of Prehospital Lung Ultrasound in EMS: A Multicenter Pilot Study","Inclusion Criteria:\n\n* Patient treated by Emergency Medical Services\n* Complaint of dyspnea\n\nAt least one of the following:\n\n* Oxygen saturation \\\u003C94% on room air\n* Abnormal lung sounds\n* Increased work of breathing\n* Pedal edema\n* Orthopnea\n\nExclusion Criteria:\n\n* Pediatric patients (\\\u003C18)\n* Traumatic etiology\n* Cardiac arrest at any point prehospitally\n* No ultrasound-trained paramedic involved in patient's care",{"count":465,"type":23},1000,[26],"The goal of this prospective nonrandomized study is to determine if prehospital lung ultrasound findings result in a change in patient management. This study will look at how lung ultrasound exam improves diagnosis of respiratory distress in patients being treated by Emergency Medical Services, such as patients with heart failure. Additional questions include:\n\n* How well can paramedics obtain and interpret ultrasound images?\n* How does ultrasound use change treatment received by patients?\n* How does ultrasound use impact patient outcomes? Participants will receive a lung ultrasound exam, but otherwise receive standard evaluation and care. Patients who receive ultrasound will be compared to those who did not receive ultrasound for logistical reasons and patients from before the use of ultrasound. Ultrasound will not be withheld from any patient for the purposes of the study.",[469,470],"Congestive Heart Failure(CHF)","Pulmonary Edema",[472,473,474,470,475,476],"Ultrasound","Emergency Medical Services","Pulmonary Ultrasound","Congestive Heart Failure","Paramedic",{"date":452,"type":39},{"date":41,"type":23},{"date":480,"type":23},"2028-12",{"name":45,"class":46},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":18,"minAge":490,"maxAge":491,"enrollmentInfo":492,"targetDuration":4,"studyType":24,"phases":493,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":93},"100424231","virtual-cycling-environments-for-persons-with-parkinson-disease-100424231","NCT04804202","Virtual Cycling Environments for Persons With Parkinson Disease","Virtual Cycling Environments (VCYCLE) Increases Exercise Intensity of Persons With Parkinson Disease","VCYCLE_PD","Inclusion Criteria:\n\n1. Diagnosis of Parkinson's disease\n2. Hoehn and Yahr stages II-III,\n3. 45-75 years old\n4. able to ride a stationary upright bicycle\n5. able to sign informed consent.\n\nExclusion Criteria:\n\n1. Have a recent history of severe heart disease, severe lung disease, uncontrolled diabetes, traumatic brain injury or neurological disorder other than Parkinson Disease.\n2. Are unable to follow directions or sign a consent form\n3. Do not have adequate vision or hearing ability to see or hear a television\n4. Have unstable medical condition or musculoskeletal disorder such as severe arthritis, recent knee surgery, hip surgery, or any other condition that the investigators determine would impair the ability to ride the bicycle\n5. Have any other medical condition that prevents bicycling\n6. Have moderate depression","45 Years","75 Years",{"count":129,"type":23},[26],"This study asks three questions about Persons with Parkinson Disease that use a bicycle for exercise. 1. Does the use of virtual reality increase the intensity and and enjoyment of the experience compared to bicycling without virtual reality? 2. Does the way in which the bicycling (interval compared to continous) is performed affect the experience? 3. How does the way the virtual reality is delivered (with goggles or projected on a screen) affect the experience?",[496],"Parkinson Disease",[498,499,500,501,502],"virtual reality","exercise","cardiovascular intensity","neuromuscular intensity","enjoyment",{"date":452,"type":39},{"date":505,"type":39},"2021-02-08",{"date":507,"type":23},"2027-12-30",{"name":45,"class":46},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":18,"minAge":516,"maxAge":19,"enrollmentInfo":517,"targetDuration":4,"studyType":24,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":529,"locationsCount":93},"100616311","sleep-treatment-for-teens-rct-phase-100616311","NCT07303959","Sleep Treatment for Teens (RCT Phase)","Sleep Treatment for Teens","Inclusion:\n\n1. Age 14-18 years old.\n2. Recent hospitalization due to suicide risk (i.e., suicide attempts, aborted\u002Finterrupted attempts, or suicide ideation with intent and\u002For a plan) using an abbreviated version of the semi-structured and well-validated Columbia Suicide Severity Rating Scale (C-SSRS; Posner et al., 2011). Regarding recency, adolescents will need to complete the baseline within three months (Study 1) or 45 days (Study 2) of discharge in order to capture the high-risk post-discharge period, which is up to 3 months following discharge from acute psychiatric hospitalization (Chung et al., 2017).\n3. Clinically significant insomnia symptoms: SCI scores ≤16 will be used to recruit a sample with clinically significant insomnia symptoms. The ISI will also be administered to gain additional information about the nature of adolescents' sleep problems in order to confirm primary insomnia. ISI scores may also be obtained via chart review when applicable\n4. Access to or willingness to use a compatible Smart Device. SleepioTM works with any internet connection (cellular or Wifi) on any iOS device running iOS 10.3 or later or on any Android device running Android OS 8.0 or later. Metricwire is compatible with all devices that SleepioTM is compatible with. If an interested adolescent does not have access to their own smart device, the research team will offer them a loaner device for the duration of the treatment\u002Ffollow-up phase.\n\nAdolescents will be excluded based on the following exclusion criteria:\n\n1. Prior CBT-I treatment, which would indicate lack of response to a prior reasonable dose of this treatment.\n2. Bipolar disorder given that certain components of CBT-I (e.g., sleep restriction) may be risky for this population.\n3. Substance use disorder that is primary to insomnia which would require alternative treatment.\n4. Presence of factors that may reduce participants' ability to consent or complete the study procedures (e.g., current psychosis, other-directed violence; severe cognitive impairment, non-English speaking).\n5. Unwillingness to wear wrist actigraphy or complete the EMA surveys.\n6. Not having a parent willing to provide permission (if participant is a minor) or to consent to their own participation (required for all adolescents). Eligibility will not be based on biological sex, gender identity, race, or ethnicity. These variables will be assessed during screening to compare those who are and are not eligible.\n7. Having a sibling who has enrolled in the study.","14 Years",{"count":178,"type":23},[26],"The purpose of this research study is to compare (vs. treatment as usual) a brief (6-session), empirically supported, and highly disseminable version of digital (i.e., smartphone or web-based) cognitive behavioral therapy for insomnia (dCBT-I), called SleepioTM, in suicidal adolescents with co-occurring insomnia during the high-risk post-hospitalization period. Suicide is the 2nd leading cause of death among adolescents. Sleep problems, such as insomnia symptoms-the most common sleep problem in youth-may be a particularly promising treatment target to reduce suicide risk in adolescents. The investigators propose to test the feasibility, acceptability, and effectiveness of dCBT-I in a two-site (Rutgers and Old Dominion University) pilot study trial. Adolescents, 14-18 years-old, recently hospitalized for suicide risk with co-occurring insomnia (n=80, 50% at each site), will receive either dCBT-I (six weekly, 20-minute sessions) plus post-hospitalization treatment-as-usual (TAU) or TAU alone. Adolescents will complete assessments pre-treatment, during the treatment phase including at the end of treatment, and 1-month follow-up post-treatment.",[521,522,523],"Sleep Problems","Suicidal Ideation","Suicidal Behavior","2026-07-08",{"date":139,"type":39},{"date":527,"type":39},"2025-06-02",{"date":278,"type":23},{"name":45,"class":46},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":75,"minAge":19,"maxAge":537,"enrollmentInfo":538,"targetDuration":4,"studyType":24,"phases":539,"briefSummary":540,"conditions":541,"keywords":543,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":143},"100601800","remote-patient-monitoring-for-chronic-hypertension-during-pregnancy-reach-100601800","NCT07115199","Remote Patient Monitoring for Chronic Hypertension During Pregnancy (REACH)","REACH","Inclusion Criteria:\n\n* Age 18 or older\n* Patients with a viable pregnancy \\\u003C23 weeks of gestation\n* Chronic hypertension is defined as: 1) Currently receiving treatment for hypertensive disorders OR 2) Newly diagnosed or untreated chronic hypertension is defined as systolic blood pressure \\>=140 mm Hg or diastolic blood pressure \\>=90 mm Hg prior to 20 weeks of gestation\n* Viable pregnancy \\\u003C23 weeks of gestation\n* Ability to follow directions\n* Ability to consent\n* Speak English or Spanish\n\nExclusion Criteria:\n\n* Known secondary cause of hypertension\n* Known major fetal anomaly\n* Known fetal demise\n* Suspected fetal growth restriction\n* Membrane rupture\n* Planned termination\n* Plan to deliver outside of the RWJ Barnabas Health system\n* Known sensitivity to labetalol or nifedipine\n* Unlikely to follow up, in the opinion of the study staff.\n* Any medical condition that the providers feel is a contraindication to the REACH algorithm.\n* Unwillingness to take blood pressure at home","55 Years",{"count":152,"type":23},[26],"We hypothesize that frequent remote monitoring of blood pressure and real-time antihypertensive medication titration will optimize pregnancy outcomes in a clinically meaningful and cost-effective manner compared to the current standard of care. Therefore, this pilot study, as part of the K12 training support, will evaluate the feasibility of a randomized clinical trial to treat mild chronic hypertension with medication therapy to a blood pressure goal of less than 140\u002F90 mmHg based on remote daily patient monitoring compared to in-office blood pressure readings.",[542],"Chronic Hypertension in Pregnancy",[544,545],"Chronic hypertension in pregnancy","Remote Patient Monitoring","2026-07-07",{"date":524,"type":39},{"date":549,"type":23},"2026-11-01",{"date":551,"type":23},"2029-06-30",{"name":45,"class":46},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":17,"sex":75,"minAge":19,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":24,"phases":561,"briefSummary":562,"conditions":563,"keywords":565,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":143},"100493305","phase-2-the-effect-of-sulfasalazine-on-crh-levels-in-pregnant-women-100493305","NCT05703425","The Effect of Sulfasalazine on CRH Levels in Pregnant Women","The Effect of Sulfasalazine on CRH Levels in Pregnant Women With a History of Pre-Term Birth: A Randomized Controlled Trial","Inclusion Criteria:\n\n* \\> 18 years of age\n* Singleton pregnancy\n* Participants with a history of prior preterm birth in a previous pregnancy\n* Participants must be between 12 and 22 weeks gestation.\n* Participants must have their pregnancy dates confirmed by ultrasound.\n\nExclusion Criteria:\n\n* Participants \\\u003C 18 years old\n* Participants with a cervical length \\\u003C 25 mm\n* Participants with a multiple gestation\n* Cerclage\n* Progesterone administration\n* Unwilling or unable to swallow the study agent capsule or consume an inert ingredient in the study agent capsule\n* Acute liver disease or known liver abnormalities\n* Other significant chronic medical or psychiatric illness that, in the investigator's opinion, would prevent participation in the study\n* Known hypersensitivity to sulfasalazine\n* Known glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* History of severe asthma\n* Digoxin use\n* Porphyria\n* Intestinal obstruction\n* Urinary tract obstruction\n* Hepatic dysfunction\n* Renal dysfunction\n* Blood dyscrasia such as agranulocytosis, aplastic anemia.",{"count":152,"type":23},[131],"The goal of this randomized clinical trial is to assess sulfasalazine as a potential treatment to prevent recurrent preterm birth. The main questions it aims to answer are:\n\n* Does sulfasalazine down regulate corticotropin releasing hormone (CRH) levels in pregnant persons with a prior history of preterm birth?\n* Does sulfasalazine reduce the incidence of recurrent preterm birth in pregnant persons given drug vs. controls?\n\nConsenting participants will be randomized to receive sulfasalazine or to a control group and will undergo serial blood draws to assess plasma CRH levels.",[564],"Preterm Birth",[566,567,568,569],"preterm birth","sulfasalazine","corticotropin releasing hormone","randomized controlled trial",{"date":351,"type":39},{"date":572,"type":39},"2023-03-01",{"date":574,"type":23},"2028-06-30",{"name":45,"class":46},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":17,"sex":18,"minAge":77,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":24,"phases":584,"briefSummary":585,"conditions":586,"keywords":589,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":143},"100493257","vibratory-stimulation-to-improve-balance-recovery-100493257","NCT05702801","Vibratory Stimulation to Improve Balance Recovery","Subsensory Stochastic Vibratory Stimulation to Assess and Improve Aging Related Proprioceptive Deficits Associated With Balance Recovery","Inclusion Criteria:\n\n* age 65 years or older\n* the ability to understand study instructions.\n\nExclusion Criteria:\n\n* disorders associated with severe motor and balance deficits, including stroke, Parkinson's disease, severe arthritis, lower-extremity amputation, spinal cord pathologies (e.g., spinal stenosis), and diabetes\n* history of severe vestibular disorder such as bilateral vestibular hypofunction or poorly-compensated unilateral vestibular hypofunction, or Dizziness Handicap Inventory (DHI) \\> 40\n* central nervous disease\n* cognitive impairment (MoCA score\\\u003C20)\n* vision problems including cataract, presbyopia, and similar problems that can influence balance\n* sedating medication or alcohol consumption within 24 hours.",{"count":129,"type":23},[26],"Falls are the primary cause of traumatic injury in older adults, and tripping is the leading cause of falls. A robust method for improving aging-related proprioceptive deficits is lacking, while strong evidence shows that proprioception deficits are highly associated with poor balance recovery from tripping. Previous research suggested that stochastic vibratory stimulation (SVS) can influence proprioception (i.e., muscle spindle function) among healthy controls; however, it is not clear how older adults with deficits in muscle spindle function would react to SVS. In previous work the investigators showed promising findings of standing balance and timed-up-and-go (TUG) improvements using SVS among high fall risk older adults with history of fall 15-18. They will implement SVS in the current project to improve aging-related proprioceptive deficits. The hypothesis is that SVS improves muscle spindle function and balance recovery from tripping in older adults with proprioceptive deficits.",[587,588],"Fall","Fall Injury",[590,591,592],"Balance recovery","stochastic stimulation intervention","Older adults","2026-07-06",{"date":524,"type":39},{"date":596,"type":39},"2024-05-01",{"date":598,"type":23},"2029-09-01",{"name":45,"class":46},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":75,"minAge":19,"maxAge":127,"enrollmentInfo":608,"targetDuration":4,"studyType":24,"phases":609,"briefSummary":610,"conditions":611,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":143},"100642812","adaptive-daily-mr-guided-adjuvant-pelvic-therapy-endometrial-cancer-100642812","NCT07643012","Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer","Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer: A Phase I\u002FII Feasibility Study","ADAPT-EC","Inclusion Criteria:\n\n1. Histologically confirmed endometrial carcinoma (endometrioid, serous, clear cell, carcinosarcoma, or dedifferentiated histology).\n2. Indication for adjuvant pelvic radiotherapy (± vaginal brachytherapy) for HIR defined by the ASTRO guidelines and GOG-99(7, 9) :\n3. Age\n4. High-grade histology (grade 2-3)\n5. Depth of myometrial invasion\n6. LVSI\n7. Positive pelvic nodes\n8. Cervical stromal invasion\n9. Presence of poor prognostic molecular markers\n10. Age ≥18 years.\n11. Ability to provide informed consent.\n12. Eligible to receive adjuvant systemic therapy, if indicated, with a minimum 3-week interval between chemotherapy and radiotherapy.\n13. Willing and able to complete EORTC QLQ-C30 and EN-24 questionnaires in a validated language version.\n\nExclusion Criteria:\n\n1. Prior pelvic radiotherapy.\n2. Contraindication to pelvic radiotherapy (e.g., active connective tissue disorder or inflammatory bowel disease).\n3. Presence of a hip prosthesis that would compromise treatment planning or delivery.\n\n   \\-",{"count":103,"type":23},[26],"To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.",[612],"Endometrial Cancer","2026-07-01",{"date":593,"type":39},{"date":616,"type":39},"2026-06-09",{"date":618,"type":23},"2029-06",{"name":45,"class":46},{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":628,"targetDuration":4,"studyType":24,"phases":629,"briefSummary":630,"conditions":631,"keywords":633,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":641,"leadSponsor":642,"locationsCount":93},"100578660","virtual-diabetes-care-for-adults-with-type-2-diabetes-on-medicaid-and-insulin-therapy-100578660","NCT06814184","Virtual Diabetes Care for Adults With Type 2 Diabetes on Medicaid and Insulin Therapy","Nurse-led App Intervention to Improve Glycemic Control in Patients With Insulin-treated Type 2 Diabetes on Medicaid","virtual care","Inclusion Criteria:\n\n* A1C \\>7 for age 18-64, A1C\\>8 for age 65 or older within 12 months prior baseline\n* A1C\\>7 for age 18-64, A1c\\>8 for age 65 or older at baseline\n* Medicaid recipient or dual Medicaid and Medicare recipient\n* Age 18 or older\n* Type 2 diabetes\n* On insulin therapy\n* Owning and using Android or iOS smartphone for at least 6 months\n* English proficiency\n* Adequate vision to read text messages on their current smartphone\n* Smartphone use proficiency. Smartphone proficiency will be self-reported and determined by telephone as the ability to use a smartphone in ways other than emailing, texting, and making phone calls.\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients with cognitive impairment who will be screened with the Six-Item Screener to Identify Cognitive Impairment Among Potential Research Subjects.",{"count":129,"type":23},[26],"This 12-month pilot tests a nurse-led, app-based intervention to improve diabetes self-management for Medicaid patients. It includes MyChart messaging to give education, phone help on problem-solving with clinicians, and using a diabetes app to track data. The study aims to enhance self-management behaviors through health technology.",[632],"Type 2 Diabetes",[634,635,636,637],"diabetes app","behavioral intervention","self-management","diabetes",{"date":639,"type":39},"2026-07-02",{"date":165,"type":39},{"date":327,"type":23},{"name":45,"class":46},""]